MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Thekla

Ich wünsche einen schönen guten Morgen und Start in den Börsen Dienstag. Kommt wie immer gut aus der Koje und zum Job und denn anderen allen einen schönen Urlaub und erholsame Tage wo es euch auch immer hin verschlagen hat. So Dienstag, was wird es heißen, wir werden es sehen. So der Hund 🐕 wartet schon, also bis später und grün wäre wieder toll ,und wenn es nur wenig ist.⛴️⚘️🙋‍♂️

Schlaft gut meine Lieben. Mögen ist ein neuer Tag. Grüner Dienstag. Auf gehts BioNTech 🍀🍀🍀

The Pfizer-BioNTech vaccine confers moderate protection against COVID-19 in children 1. Two doses of the Pfizer-BioNTech vaccine resulted in moderate protection against SARS-CoV-2 infection in children aged 5 to 11. 2. The Pfizer-BioNTech vaccine also provided moderate protection against symptomatic coronavirus disease 2019 (COVID-19) in children aged 5 to 11. Evidence Rating Level: 1 (Excellent) Study Rundown: The development of vaccinations to protect against COVID-19 has resulted in fewer and less severe infections. Though, the vaccine efficacy has been predominantly studied in adults. Children aged 5 to 11 are also susceptible to SARS-CoV-2 infection, though they are more likely to present with asymptomatic infection or milder symptoms as compared to older adults. However, the spread of the delta variant has increased the incidence of pediatric COVID-19-related hospitalizations in the United States. Moreover, the omicron variant, which has been the most recent dominant variant, has also been shown to infect children. The infectivity and severity of infection of the omicron variant and associated vaccine effectiveness against it have not been well evaluated in children. Thus, there is a gap in knowledge as to understanding whether the Pfizer-BioNTech vaccine confers protection against the omicron variant in children. Overall, this study found that the Pfizer-BioNTech vaccine showed moderate protection against COVID-19 infection and symptoms among children aged 5 to 11, during a period in which omicron was the prevalent variant. This study was limited by only being able to measure short-term effectiveness and the possibility of residual confounding variables, such as behavioral factors of wearing masks, were not assessed. Nevertheless, the study’s findings are significant as they demonstrate that the Pfizer-BioNTech confers moderate protection against COVID-19 in children ages 5 to 11.

Jeder Blinde erkennt das wir hier in etwas ganz großem investiert sind und erst am Anfang der Story stehen. SAP hat klein angefange, Apple und Amazon auch. Biontech fängt auch gerade erst an

Wir sehen hier auch wieder das ATH 👌📈

25.07.2022 22:48 Dow Jones schließt im Plus Technologiewerte lassen vor Zahlenflut Federn https://www.n-tv.de/23487464

lol, wenn es nicht bei Moderna funktioniert, bei Biontech klappt es immer

https://api.boerse-go.de/charting/6149576.image?application=grid&template=config&width=640&height=360&client_id=grid

deshalb spielt Moderna gerade verrückt after hour.

https://www.cnbc.com/2022/07/25/walmart-cuts-second-quarter-guidance-as-it-sees-slower-growth-due-to-inflation.html

Walmart guidance hat den Nasdaq direkt wieder runtergezogen

Oder der Rest der Chart Menschen, ich bin/war ja eh nie so einer

Vielleicht sieht @hotzenplotz5 das anders, aber das war immer meine Linie zur Trendwende